HCT-116 Oxaliplatin-Resistant Colorectal Cancer Model Service

The HCT-116 Oxaliplatin-Resistant Colorectal Cancer Model Service supplies an in vivo recreation of FOLFOX failure: the KRAS G13D, MLH1-null HCT-116 adenocarcinoma is pushed through continuous diaminocyclohexane-platinum pressure until resistance is consolidated across DNA-repair upregulation, redox detoxification, autophagy-biased survival, and a stemness program that leaves tumors harder to kill and harder to eradicate. Alfa Cytology delivers this program with authenticated HCT-116 banks, documented parental sensitivity baselines, validated intraperitoneal oxaliplatin dosing sustained to breakthrough, and endpoint analysis that quantifies ERCC1-driven repair activity, ABC-transporter and GST-pi expression, and CD133/CD44 stemness markers — delivering resistant cohorts whose phenotype is confirmed across the repair, detoxification, and stemness axes that define oxaliplatin failure.

Overview of HCT-116 Oxaliplatin-Resistant Colorectal Cancer Model

Oxaliplatin, the diaminocyclohexane-bearing platinum approved in the early 2000s, anchors the FOLFOX regimen that remains first-line for metastatic colorectal cancer. Its platinum–DACH adducts are bulkier and more helix-distorting than cisplatin's, poorly processed by the mismatch-repair system that interprets conventional platinum damage — a chemistry that reshapes how resistance evolves. HCT-116, isolated by Brattain and colleagues in 1979 from a 44-year-old man's colon adenocarcinoma, is one of oncology's best-characterized models: heterozygous KRAS G13D, PIK3CA H1047R, a truncating MLH1 defect rendering it mismatch-repair-deficient and microsatellite-instability-high, wild-type p53, and a serine-45 β-catenin deletion that locks Wnt signaling on. Highly tumorigenic with an in vivo doubling time of roughly a week, it grows predictably in immunodeficient mice and has generated an unusually rich family of oxaliplatin-resistant derivatives.

Fig 1. Dose-response of the HCT116 oxaliplatin-resistant model — variable-slope nonlinear regression viability curves of parental HCT116 (IC50 0.54 μM) versus OXrHCT116 (IC50 25.98 μM, ~48-fold resistance) by extra sum-of-squares F test. (Heinzle, Christine, et al., 2026)

Those derivatives define the resistance landscape. HCT-116/OXR, selected stepwise, carries a six-fold IC50 shift — 31.6 versus 5.1 micromolar — together with cross-resistance to cisplatin and a proteomic signature dominated by ERCC1 and ABCG2 elevation, with ERCC1 knockdown measurably re-sensitizing the cells; the HCT-116/L-OHP line reaches a 17-fold resistance index that survives freeze-thaw recovery; and pulse-exposed HCT116 oxpl-R cells display the defining survival phenotype of platinum resistance — they still arrest at the G2/M boundary under drug, but the arrest no longer terminates in sub-diploid death. Around this core lie the accessory programs: XRCC1/XRCC2-dependent repair modulation, GST-pi and glutathione detoxification with MRP-family and P-glycoprotein upregulation, beclin-1–driven autophagy under miR-409-3p control, Bcl-2 elevation, and — most consequentially for in vivo work — a stemness program in which oxaliplatin-resistant cells enrich for CD133, CD44, SOX2 and OCT4, gain invasive and tumorigenic capacity, and wire their survival through the CXCR4–AKT/ERK/NF-κB axis. Exposure schedule itself shapes evolution: continuous versus intermittent regimens select measurably different genomic and transcriptomic landscapes. And the phenotype carries an exploitable seam — oxaliplatin-resistant HCT-116 cells are markedly sensitized to TRAIL-receptor–mediated death. Together these properties make the model a live map of FOLFOX failure, from repair-pathway and transporter targeting to death-receptor combinations and schedule-optimization studies.

Principles of HCT-116 Oxaliplatin-Resistant Colorectal Cancer Model Construction

The construction principle is platinum pressure applied within a mismatch-repair-deficient genome whose p53 is still intact — a combination that redirects selection away from simple apoptosis avoidance and toward repair capacity, detoxification, and stemness. Oxaliplatin's bulky DACH adducts are poorly handled by the MMR machinery, so the MLH1-null background of HCT-116 does not shield the tumor the way it would against cisplatin; instead, resistance consolidates around excision-repair upregulation and phenotypic plasticity. Two construction routes serve the model: chronic in vivo selection, in which xenografts are dosed intraperitoneally until breakthrough at a pre-agreed threshold, and transplantation of in vitro–selected derivatives from the characterized HCT-116/OXR, HCT-116/L-OHP, or oxpl-R families. Both rest on the same discipline: a quantified parental sensitivity baseline, fixed breakthrough criteria, and an endpoint panel that measures repair, detoxification, survival, and stemness together.

Our Services

Alfa Cytology runs this model as a repair-and-stemness mapping program: HCT-116 banks are STR-authenticated with KRAS G13D, PIK3CA H1047R and MLH1-null status reconfirmed and parental oxaliplatin sensitivity quantified before inoculation, intraperitoneal dosing continues uninterrupted until breakthrough at pre-set thresholds, and endpoint panels quantify ERCC1 repair activity, transporter expression, autophagy status, and CD133/CD44 stemness together — so the FOLFOX-resistant tumors your strategies confront come with their resistance architecture documented.

Workflow of HCT-116 Oxaliplatin-Resistant Colorectal Cancer Model Construction

Building oxaliplatin resistance in an HCT-116 program is a study in layered defenses surfacing under sustained platinum pressure within a mismatch-repair-deficient genome. The sequence below follows a typical engagement from bank verification to resistant cohorts annotated across repair, detoxification, survival, and stemness axes.

1. Study design and route selection: The plan fixes the construction route — chronic in vivo selection or transplantation of a characterized in vitro–selected derivative — together with group sizes, intraperitoneal dosing schedules, vehicle controls, and the quantitative breakthrough threshold that will define resistance.
2. Cell authentication and baseline profiling: HCT-116 banks are STR-authenticated and mycoplasma-cleared, KRAS G13D and PIK3CA H1047R status is reconfirmed, MLH1-null/MSI-H status is documented, and baseline oxaliplatin IC50 values are recorded to anchor downstream resistance ratios.
3. In vitro resistance establishment (where selected): Parental cells are stepped through escalating oxaliplatin exposure — continuously or by pulse regimens, which select distinct landscapes — until a stable derivative with documented IC50 shifts and cross-resistance profiles is available for in vivo work.
4. Host preparation and tumor inoculation: Female BALB/c nude or NOD-SCID mice are randomized and implanted subcutaneously with a standardized inoculum — classically 5 × 10⁶ cells, frequently in Matrigel — and tumors are grown to the pre-specified starting volume.
5. Chronic intraperitoneal oxaliplatin dosing and breakthrough surveillance: Oxaliplatin dosing begins at treatment initiation and continues without interruption; tumor dimensions are captured on a fixed schedule, refractoriness is quantified as tumor-growth inhibition relative to vehicle, and breakthrough kinetics are archived.
6. Endpoint characterization: Resistant and control tumors are excised and profiled by H&E with γ-H2AX adduct-burden assessment, ERCC1, ABCG2, GST-pi, LC3B, CD133/CD44 and Ki-67 immunostaining, and cleaved caspase-3/PARP apoptosis assays, with TRAIL-pathway markers added where combination studies require.
7. Data integration and reporting: Tumor-growth kinetics, inhibition ratios, and molecular annotations are consolidated — with repair, detoxification, survival, and stemness axes separated for interpretation — into the final study report.

Fig 2. HCT-116 Oxaliplatin-Resistant Colorectal Cancer Model Construction Workflow.

Case Study-HCT-116 Oxaliplatin-Resistant Colorectal Cancer Model Development

Alfa Cytology has applied the HCT-116 oxaliplatin-resistance platform in preclinical programs addressing FOLFOX failure in colorectal cancer, including repair-pathway targeting, transporter modulation, and death-receptor combination strategies. Studies of this scope have covered authenticated bank preparation with documented baseline sensitivity, subcutaneous xenograft establishment, uninterrupted intraperitoneal oxaliplatin dosing under pre-agreed breakthrough thresholds, and terminal characterization spanning repair activity, transporter expression, autophagy status, and stemness markers — producing tumor-growth, inhibition-ratio and mechanism-axis datasets used for internal candidate decisions. Further detail can be shared upon request as your program defines its direction.

Why Choose Alfa Cytology?

Oxaliplatin resistance in an MLH1-null, p53-wild-type line does not consolidate the way cisplatin resistance does in p53-null cells — the selection logic differs, and the endpoint panel must follow it. Alfa Cytology reads the repair, detoxification, and stemness layers in every cohort and reports them as one architecture.

• STR-authenticated HCT-116 banks with reconfirmed KRAS G13D, PIK3CA H1047R and MLH1-null status.
• Documented parental oxaliplatin IC50 baselines and cross-resistance panels for every bank.
• Both construction routes available: chronic in vivo selection and characterized in vitro–selected derivatives across multiple exposure regimens.
• Validated intraperitoneal dosing logistics sustaining platinum pressure from first dose to breakthrough.
• Endpoint panels spanning γ-H2AX, ERCC1, ABCG2, GST-pi, LC3B, CD133/CD44, Ki-67 and apoptosis markers, plus TRAIL-pathway markers for combination studies.
• Strictly preclinical operations — research-stage programs receive our complete attention.
• Integrated reporting that pairs growth kinetics with a four-layer resistance architecture in one package.

Contact Us

If your pipeline targets FOLFOX-refractory colorectal cancer — through repair-pathway or transporter inhibition, stemness-directed combinations, or death-receptor strategies — reach out to us to design an HCT-116 oxaliplatin-resistant study matched to your mechanism and endpoints. Contact Alfa Cytology today, and our team will return a tailored proposal with cohort designs and projected timelines.

For research use only. Not intended for any clinical use.